AstraZeneca Faces Uphill Battle In Talking U.S. Docs Into Using Brilinta

 
• By Emily Hayes

U.S. physicians say skepticism over the North American results in the pivotal PLATO study is one of many factors that’s been slowing adoption. Competition with low-cost generics is another.

AstraZeneca PLC’s plan to turn around performance of Brilinta/Brilique (ticagrelor) in the U.S. is likely to be an uphill battle, considering competition from low cost clopidogrel generics and skepticism in the cardiology community about the North American results in the PLATO pivotal trial, among many other factors.

Approved in the U.S

More from Clinical Trials

More from R&D